{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T02:09:29Z","timestamp":1775873369234,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T00:00:00Z","timestamp":1351468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1038\/aps.2012.135","type":"journal-article","created":{"date-parts":[[2012,10,29]],"date-time":"2012-10-29T13:19:09Z","timestamp":1351516749000},"page":"1431-1440","source":"Crossref","is-referenced-by-count":38,"title":["The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation"],"prefix":"10.1038","volume":"33","author":[{"given":"Jun-jie","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,10,29]]},"reference":[{"key":"BFaps2012135_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-198611030-00001","volume":"3","author":"L Bertilsson","year":"1986","unstructured":"Bertilsson L, Tomson T . Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update. Clin Pharmacokinet 1986; 3: 177\u201398.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps2012135_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2165\/00003088-197803020-00003","volume":"3","author":"L Bertilsson","year":"1978","unstructured":"Bertilsson L . Clinical pharmacokinetics of carbamazepine. Clin Pharmacokinet 1978; 3: 128\u201343.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps2012135_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/00007691-199812000-00012","volume":"6","author":"J Potter","year":"1998","unstructured":"Potter J, Donnelly A . Carbamazepine-10,11-epoxide in therapeutic drug monitoring. Ther Drug Monit 1998; 6: 652\u20137.","journal-title":"Ther Drug Monit"},{"key":"BFaps2012135_CR4","unstructured":"Garnett W . Antiepileptic drugs. In: Schumacher G, editor. Therapeutic drug monitoring. Connecticut: Appleton and Lange Norwalk; 1995. p351\u20136."},{"key":"BFaps2012135_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1081\/CLT-120015836","volume":"40","author":"R Winnicka","year":"2002","unstructured":"Winnicka R, Topacinski B, Szymczak W, Szymanska B . Carbamazepine poisoning: elimination kinetics and quantitative relationship with carbamazepine 10,11-epoxide. J Toxicol Clin Toxicol 2002; 40: 759\u201365.","journal-title":"J Toxicol Clin Toxicol"},{"key":"BFaps2012135_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2165\/00003088-199631030-00004","volume":"31","author":"E Spina","year":"1996","unstructured":"Spina E, Pisani F, Perucca E . Clinically significant pharmacokinetic drug interactions with carbamazepine. An Update. Clin Pharmocokinet 1996; 31: 198\u2013214.","journal-title":"Clin Pharmocokinet"},{"key":"BFaps2012135_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"P Patsalos","year":"2008","unstructured":"Patsalos P, Berry D, Bourgeois B . Antiepileptic drugs \u2014 best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239\u201376.","journal-title":"Epilepsia"},{"key":"BFaps2012135_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.yebeh.2008.12.006","volume":"14","author":"R Manjunath","year":"2009","unstructured":"Manjunath R, Davis K, Candrilli S, Ettinger A . Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav 2009; 14: 372\u20138.","journal-title":"Epilepsy Behav"},{"key":"BFaps2012135_CR9","first-page":"238","volume":"457","author":"W Rosenfeld","year":"2004","unstructured":"Rosenfeld W, Bramley T, Meyer K . Patient compliance with topiramate vs other antiepileptic drugs: A claims database analysis. Epilepsia 2004; 457: 238\u20139.","journal-title":"Epilepsia"},{"key":"BFaps2012135_CR10","first-page":"150","volume":"98","author":"L Stanaway","year":"1985","unstructured":"Stanaway L, Lambie D, Johnson R . Non-compliance with anticonvulsant therapy as a cause of seizures. N Z Med J 1985; 98: 150\u20132.","journal-title":"N Z Med J"},{"key":"BFaps2012135_CR11","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S1525-5050(02)00037-9","volume":"3","author":"J Cramer","year":"2002","unstructured":"Cramer J, Glassman M, Rienzi V . The relationship between poor medication compliance and seizures. Epilepsy Behav 2002; 3: 338\u201342.","journal-title":"Epilepsy Behav"},{"key":"BFaps2012135_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1528-1167.2007.01414.x","volume":"49","author":"K Davis","year":"2008","unstructured":"Davis K, Candrilli S, Edin H . Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008; 49: 446\u201354.","journal-title":"Epilepsia"},{"key":"BFaps2012135_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003088-200140010-00002","volume":"1","author":"P Bonate","year":"2001","unstructured":"Bonate P . A brief introduction to Monte Carlo simulation. Clin Pharmacokinet 2001; 1: 15\u201322.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps2012135_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2710.2004.00557.x","volume":"29","author":"Z Jiao","year":"2004","unstructured":"Jiao Z, Shi X, Zhao Z, Zhong M . Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data. J Clin Pharm Ther 2004; 29: 247\u201356.","journal-title":"J Clin Pharm Ther"},{"key":"BFaps2012135_CR15","first-page":"445","volume":"22","author":"Z Jiao","year":"2002","unstructured":"Jiao Z, Zhong M, Shi X, Zhang J . HPLC simultaneous determination of carbamazepine, carbamazepine-10,11-epoxide, phenytoin in human serum. Chin J Pharm Anal 2002; 22: 445\u20139.","journal-title":"Chin J Pharm Anal"},{"key":"BFaps2012135_CR16","first-page":"544","volume":"(12)","author":"R Zhang","year":"1990","unstructured":"Zhang R, Qu Z, Yu L, Wu Y, Fan C . Comparison on bioavailability of domestic and imported carbamazepine tablets in normal volunteers. Chin J Pharm 1990; (12): 544\u20135.","journal-title":"Chin J Pharm"},{"key":"BFaps2012135_CR17","doi-asserted-by":"publisher","first-page":"11S","DOI":"10.1046\/j.1365-2125.2001.00394.x","volume":"52 Suppl 1","author":"M Eadie","year":"2001","unstructured":"Eadie M . Therapeutic drug monitoring--antiepileptic drugs. Br J Clin Pharmacol 2001; 52 Suppl 1: 11S\u201320S.","journal-title":"Br J Clin Pharmacol"},{"key":"BFaps2012135_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1528-1157.1979.tb04808.x","volume":"20","author":"L Gram","year":"1979","unstructured":"Gram L, Flachs H, Wurtz-Jorgensen A, Parnas J, Andersen B . Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 1979; 20: 303\u201311.","journal-title":"Epilepsia"},{"key":"BFaps2012135_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0896-6974(05)80094-5","volume":"6","author":"CL Harden","year":"1993","unstructured":"Harden CL, Zisfein J, Atos-Radzion E C, Tuchman AJ . Combination valproate-carbamazepine therapy in partial epilepsies resistant to carbamazepine monotherapy. J Epilepsy 1993; 6: 91\u20134.","journal-title":"J Epilepsy"},{"key":"BFaps2012135_CR20","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","volume":"41","author":"C Deckers","year":"2000","unstructured":"Deckers C, Czuczwar S, Hekster Y, Keyser A, Kubova H, Meinardi H, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000; 41: 1364\u201374.","journal-title":"Epilepsia"},{"key":"BFaps2012135_CR21","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1185\/030079905X59120","volume":"21","author":"A Ahmad","year":"2005","unstructured":"Ahmad A, Garnett W . Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. Curr Med Res Opin 2005; 21: 1363\u20138.","journal-title":"Curr Med Res Opin"},{"key":"BFaps2012135_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1185\/030079903125002144","volume":"19","author":"W Garnett","year":"2003","unstructured":"Garnett W, Mclean A, Zhang Y, Clausen S, Tulloch S . Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules. Curr Med Res Opin 2003; 19: 519\u201325.","journal-title":"Curr Med Res Opin"},{"key":"BFaps2012135_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","volume":"50","author":"R Faught","year":"2009","unstructured":"Faught R, Weiner J, Guerin A, Cunnington M, Duh M . Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia 2009; 50: 501\u20139.","journal-title":"Epilepsia"},{"key":"BFaps2012135_CR24","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1212\/WNL.34.9.1252","volume":"34","author":"D Schmidt","year":"1984","unstructured":"Schmidt D, Haenel F . Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: individual variation in relation to seizure frequency and type. Neurology 1984; 34: 1252\u20135.","journal-title":"Neurology"},{"key":"BFaps2012135_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1528-1157.1988.tb04408.x","volume":"29","author":"E Woo","year":"1988","unstructured":"Woo E, Chan Y, Yu Y, Chan Y, Huang C . If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia 1988; 29: 129\u201339.","journal-title":"Epilepsia"},{"key":"BFaps2012135_CR26","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/j.1365-2125.1981.tb01316.x","volume":"12","author":"D Gannaway","year":"1981","unstructured":"Gannaway D, Mawer G . Serum phenytoin concentration and clinical response in patients with epilepsy. Br J Clin Pharmacol 1981; 12: 833\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"BFaps2012135_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/00003088-200038030-00001","volume":"38","author":"E Perucca","year":"2000","unstructured":"Perucca E . Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38: 191\u2013204.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps2012135_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/bdd.473","volume":"26","author":"A Ahmad","year":"2005","unstructured":"Ahmad A, Douglas B, Barr W, Reed R, Garnett W . The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations. Biopharm Drug Dispos 2005; 26: 417\u201325.","journal-title":"Biopharm Drug Dispos"},{"key":"BFaps2012135_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1365-2710.2006.00739.x","volume":"31","author":"S Dutta","year":"2006","unstructured":"Dutta S, Reed R . Effect of delayed and\/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician. J Clin Pharm Ther 2006; 31: 321\u20139.","journal-title":"J Clin Pharm Ther"},{"key":"BFaps2012135_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/00007691-200306000-00005","volume":"25","author":"Z Jiao","year":"2003","unstructured":"Jiao Z, Zhong M, Shi X, Hu M, Zhang J . Population pharmacokinetics of carbamazepine in Chinese epilepsy patients. Ther Drug Monit 2003; 25: 279\u201386.","journal-title":"Ther Drug Monit"},{"key":"BFaps2012135_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/00007691-200306000-00021","volume":"25","author":"J Hermida","year":"2003","unstructured":"Hermida J, Tutor J . How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine-10,11-epoxide in serum samples? Ther Drug Monit 2003; 25: 384\u20138.","journal-title":"Ther Drug Monit"},{"key":"BFaps2012135_CR32","first-page":"291","volume":"20","author":"Z Jiao","year":"2004","unstructured":"Jiao Z, Zhao Z, Shi X, Zhong M . Comparison of HPLC and FPIA method in determination of carbamazepine in human serum. Chin J Clin Pharmacol 2004; 20: 291\u20134.","journal-title":"Chin J Clin Pharmacol"},{"key":"BFaps2012135_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0009-9120(01)00186-2","volume":"34","author":"S Shen","year":"2001","unstructured":"Shen S, Elin R, Soldin S . Characterization of cross reactivity by carbamazepine 10,11-epoxide with carbamazepine assays. Clin Biochem 2001; 34: 157\u20138.","journal-title":"Clin Biochem"},{"key":"BFaps2012135_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1528-1157.1998.tb01372.x","volume":"39","author":"W Garnett","year":"1998","unstructured":"Garnett W, Levy B, Mclean A, Zhang Y, Couch RA, Rudnic EM, et al. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia 1998; 39: 274\u20139.","journal-title":"Epilepsia"},{"key":"BFaps2012135_CR35","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1016\/S0149-2918(03)80319-3","volume":"25","author":"R Hogan","year":"2003","unstructured":"Hogan R, Garnett W, Thadani V, Group CS . Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders an open-label, to month continuation study. Clin Ther 2003; 25: 2586\u201396.","journal-title":"Clin Ther"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps2012135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2012135","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps2012135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:27:19Z","timestamp":1684412839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps2012135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,29]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["BFaps2012135"],"URL":"https:\/\/doi.org\/10.1038\/aps.2012.135","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,29]]}}}